Navigation Links
Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
Date:1/7/2008

mong existing oral OAB treatments, according to Dr. Sand. "Watson's oxybutynin gel is an elegant topical formulation that is clear, odorless and fast drying and will offer healthcare providers a unique treatment option for OAB patients," said Dr. Sand.

The Phase 3 multi-center, double blind, placebo-controlled study evaluated the efficacy and safety of OTG in 789 patients with overactive bladder. The primary objective of the study was to demonstrate that daily treatment of a 1g dose (approximately 1 mL) of OTG for 12 weeks was superior to placebo for the relief of OAB symptoms. Changes from baseline to endpoint were calculated from a three-day patient urinary diary and included a reduction in incontinence episodes and urinary frequency, and an increase in void volume. Additionally, 216 patients participated in a 14-week, open label, safety-extension study for a total of 26 weeks. During the double-blind portion of the trial, highly statistically significant improvements relative to placebo were seen on all of these endpoints.

Secondary endpoints also included a patient assessment of incontinence-specific, quality-of-life measures using multiple validated instruments including the Incontinence Impact Questionnaire (IIQ) and the King's Health Questionnaire, which indicated a significant positive effect of OTG treatment on quality-of-life total and subscale scores at endpoint in comparison with placebo.

OTG was well tolerated in the study. No serious adverse events related to the treatment were reported. Dry mouth (6.9%) and application site pruritis (2.1%) were the only treatment-related side effects reported at levels greater than 2%. Treatment-related adverse events that resulted in study discontinuation during the double-blind period were low (1.8%) and the similar for both the treatment and placebo groups.

Phase 1 studies have demonstrated that the steady-state plasma levels of oxybutynin show little fluctuation during the 24-hour dosin
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
5. Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
6. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
9. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
10. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
11. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... , Nov. 28, 2014 The market for ... reach 7.9 billion dollars in 2014 according to Kalorama ... existing equipment and growing incidence of disease are driving ... X-Ray and Digital X-Ray: World Market Analysis ... X-Ray: World Market Analysis can be obtained at: ...
(Date:11/28/2014)... ATLANTA , Nov. 28, 2014 ... (Alimera), a pharmaceutical company that specializes in the ... has entered into a Securities Purchase Agreement with ... pursuant to which Alimera will issue shares of ... price of approximately $50.0 million upon the satisfaction ...
(Date:11/27/2014)... , Nov. 27, 2014  Javon Bea Mercy ... 19, faculty and staff at Janesville Craig High School ... from Mercy Health System physicians and Janesville ... Fire Departments and the Janesville ... Care Program, dedicated to providing schools and other organizations ...
Breaking Medicine Technology:Kalorama: X-Ray and Digital X-Ray Market Nears 8 Billion This Year 2Kalorama: X-Ray and Digital X-Ray Market Nears 8 Billion This Year 3Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 2Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 3Mercy Health System, Janesville Police / Fire, provide casualty training to high school faculty 2Mercy Health System, Janesville Police / Fire, provide casualty training to high school faculty 3
... Tissues at Well-Tolerated ... Doses, ... data from a phase 1 dose-escalation trial of XL765, a,novel small molecule ... proliferation, survival, and,resistance to chemotherapy and radiotherapy. The trial is being carried ...
... III clinical trial --, CHICAGO, May 31 ... the presentation of updated results from,a 482 patient, ... dexamethasone (VcD) to vincristine, adriamycin and,dexamethasone (VAD). Results ... in the VcD arm as induction therapy and ...
Cached Medicine Technology:Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO 2Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO 3Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO 4Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO 5VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 2VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 3VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 4VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 5VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma 6
(Date:11/28/2014)... November 29, 2014 The holiday season is ... recently announced its new collection of fashionable party dresses. What’s ... off, on all these brand new outfits; the special offer ... is a renowned online supplier and it has received a ... new items are specially designed to flatter various body shapes; ...
(Date:11/28/2014)... Brosix is always making changes to ... with a more efficient, effective, and secure experience. Most ... , 1. The ability to setup local servers for ... better service customers around the globe. , 2. The ... large customers that require millions of users in one ...
(Date:11/28/2014)... November 28, 2014 Novatus, a ... its Release v5.1 which provides customers with greater ... options. , “As we continue to evolve ... provide more functionality and improved performance in response ... CEO for Novatus. “With the enhancements that we ...
(Date:11/28/2014)... Diane Walder, one of South Florida’s top cosmetic dermatologists ... Ultrashape that is designed to help her patients reduce unwanted ... Ultrashape has been praised by patients as being permanent, painless, ... other types of external fat reduction. , “If you can ... , According to Dr. Walder, Ultrashape works by targeting subcutaneous ...
(Date:11/28/2014)... Minnesota (PRWEB) November 28, 2014 ... of the few insurance marketing organizations in the ... income and asset protection marketplace. Secura Consultants is ... partnership with Principal Financial Group, a leading global ... multiple ownership interests. With the ownership interest comes ...
Breaking Medicine News(10 mins):Health News:Trendy Party Dresses For The Coming Holiday Season From Balfleet.com 2Health News:Brosix Infrastructure Architecture Changes to Benefit Users 2Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3Health News:Secura Consultants Offers Complimentary Buy-Sell Agreement Reviews 2
... The following is being,issued by the Democratic ... Marca Bristo, former Chair of the National Council ... held a conference call today in,advance of John ... on,Disability Issues in Columbus, Ohio. There is speculation ...
... results -, LAVAL, QC, July 25 /PRNewswire-FirstCall/ - ... will host a conference call on,Friday, August 8 at ... results. Labopharm will report its second quarter 2008 financial,results ... day., To access the conference call by telephone, ...
... Impaired immune response after antiretroviral therapy may be due ... -- A new study challenges the long-held belief that ... ability to restore itself after HIV patients are treated ... percent to 90 percent of HIV-infected drug users are ...
... July 25, 2008 The American Society for ... of endoscopy in the bariatric surgery patient. The rising ... success in surgical interventions led to a marked increase ... U.S., from 13,365 in 1998 to 102,794 in 2003. ...
... of jobs created in the medical field slowed in June, pharmaceutical companies ... June than in previous months. , ... Seattle, WA (PRWEB) July 25, ... slowed in June overall, pharmaceutical companies reported a different kind of slowdown ...
... -, CORONA, Calif., July 25 Watson,Pharmaceuticals, ... pharmaceutical,company, announced today that its subsidiary has commenced ... in the 40mg,strength from its Davie, Florida manufacturing ... days of marketing exclusivity for being the,first to ...
Cached Medicine News:Health News:AUDIO OF CONFERENCE CALL: National Disability Rights Leaders Dubious Over John McCain's Possible Switch on Community Choice Act, Says DNC 2Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 3Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
Medicine Products: